Trials / Completed
CompletedNCT02080221
BrUOG 292: FOLFOX-A For Metastatic Pancreatic Cancer: A Phase II Brown University Oncology Research Group Trial
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 50 (actual)
- Sponsor
- Brown University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A standard treatment for your cancer is called FOLFIRINOX (this utilizes the FDA approved chemotherapy drugs fluorouracil, leucovorin, oxaliplatin and irinotecan). In this study you will receive the chemotherapy treatment FOLFOX-A (fluorouracil, oxaliplatin, leucovorin and Abraxane ®) which substitutes irinotecan for the FDA approved chemotherapy drug Abraxane ®. Even though Abraxane is FDA approved for pancreatic cancer, the combination of Abraxane with the other 3 drugs is being investigated. Your doctors are studying the activity and side effects of FOLFOX-A in advanced (metastatic) pancreatic cancer.
Detailed description
See summary above
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | FOLFOXA |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2020-01-09
- Completion
- 2022-03-16
- First posted
- 2014-03-06
- Last updated
- 2022-08-01
- Results posted
- 2021-08-13
Locations
2 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02080221. Inclusion in this directory is not an endorsement.